Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910764 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL8017553 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL6565021 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL1134697 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4803964 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4351721 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL23646744 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4595842 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL736623 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL10715427 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-20100330596-A1 | LIPOPROTEIN SURFACTANT | ROCHE DIABETES CARE, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-2164982-A2 | LIPOPROTEIN SURFACTANT | F.HOFFMANN-LA ROCHE AG (CH) | 2010-03-24 | — | — | EP | disclosed |
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2010-02-18 | — | — | US | disclosed |
| WO-2008152380-A2 | LIPOPROTEIN SURFACTANT | OXFORD BIOSENSORS LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008048967-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | CA14, HCAR1, CCKAR | GBA1 1462/4885SLC2A1 433/4885MAPK1 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.